Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial-Reference-Cited by-同舟云学术

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

Published:2018-09 Issue: Volume:101 Page:236-243
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Carlino Matteo S.,Long Georgina V.^ORCID,Schadendorf Dirk^ORCID,Robert Caroline,Ribas Antoni^ORCID,Richtig Erika,Nyakas Marta,Caglevic Christian,Tarhini Ahmed,Blank Christian,Hoeller Christoph,Bar-Sela Gil^ORCID,Barrow Catherine,Wolter Pascal,Zhou Honghong,Emancipator Kenneth,Jensen Erin H.,Ebbinghaus Scot,Ibrahim Nageatte,Daud Adil

Funder

Merck Sharp & Dohme Corp.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis;Karlsson;Clin Cosmet Invest Dermatol,2017

2. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma;Postow;Cancer J,2012

3. Immune checkpoint blockade: a common denominator approach to cancer therapy;Topalian;Cancer Cell,2015

4. Immune checkpoint blockade: a new paradigm in treating advanced cancer;Kreamer;J Adv Pract Oncol,2014

5. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma;Journal of Clinical Oncology;2024-08-20

2. The outcome in patients with BRAF‐mutated metastatic melanoma treated with anti‐programmed death receptor‐1 monotherapy or targeted therapy in the real‐world setting;Cancer Medicine;2024-03

3. Widespread adoption of precision anticancer therapies after implementation of pathologist-directed comprehensive genomic profiling across a large US health system;2024-01-04

4. Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response;Cancers;2023-11-28

5. Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies;OncoImmunology;2023-10-04